Mucinous Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: MCN001 MIFTS: 52	Mucinous Adenocarcinoma Categories: Cancer diseases
Genes Tissues Related diseases Publications Pathways Drugs Download Expand all tables

Sources

Aliases & Classifications for Mucinous Adenocarcinoma

MalaCards integrated aliases for Mucinous Adenocarcinoma:

Name: Mucinous Adenocarcinoma ¹² ¹⁵ ⁷³

Mucin-Producing Adenocarcinoma ¹² ⁷³

Pseudomyxoma Peritonei with Unknown Primary Site ¹²

Mucin-Secreting Adenocarcinoma ¹²

Mucin-Secreting Carcinoma ¹²

Adenocarcinoma, Mucinous ⁴⁴

Mucous Carcinoma ¹²

Classifications:

MalaCards categories:
Global: Cancer diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:3030

MeSH ⁴⁴ D002288

NCIt ⁵⁰ C26712 C27379 C27825

SNOMED-CT ⁶⁸ 72495009 900006

UMLS ⁷³ C0007130 C0334368

Sources

Summaries for Mucinous Adenocarcinoma

Disease Ontology : ¹² An adenocarcinoma that derives from epithelial cells originating in glandular tissue, which produce mucin.

MalaCards based summary : Mucinous Adenocarcinoma, also known as mucin-producing adenocarcinoma, is related to endometrial mucinous adenocarcinoma and appendix adenocarcinoma. An important gene associated with Mucinous Adenocarcinoma is KRT7 (Keratin 7), and among its related pathways/superpathways are Pathways in cancer and Development EGFR signaling pathway. The drugs Bevacizumab and Capecitabine have been mentioned in the context of this disorder. Affiliated tissues include colon, prostate and appendix, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Mucinous Adenocarcinoma

Diseases related to Mucinous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 329)

#	Related Disease	Score	Top Affiliating Genes
1	endometrial mucinous adenocarcinoma	34.0	CDKN2A MUC1
2	appendix adenocarcinoma	33.6	CDX2 KRT20 KRT7
3	ovarian mucinous adenocarcinoma	33.4	CDX2 KRT20 KRT7 MUC2
4	pseudomyxoma peritonei	31.3	CDX2 KRAS KRT20 KRT7 MUC1 MUC2
5	teratoma	30.9	CDX2 KRT7 NKX2-1
6	krukenberg carcinoma	30.8	KRT20 KRT7
7	ovarian germ cell teratoma	30.8	KRT7 NKX2-1
8	transverse colon cancer	30.6	KRT20 KRT7
9	ovarian large-cell neuroendocrine carcinoma	30.6	KRT20 KRT7
10	sertoli-leydig cell tumor	30.6	KRT7 MUC1
11	nephrogenic adenoma	30.6	KRT7 MUC1
12	cystadenocarcinoma	30.6	KRT7 MUC1 MUC2
13	thymus adenocarcinoma	30.6	CDX2 KRT20 KRT7
14	rectum adenocarcinoma	30.3	CDX2 KRT20 KRT7
15	dermoid cyst	30.1	KRT20 KRT7 MUC1
16	villous adenoma	30.0	CDX2 KRAS KRT20 MUC1
17	gallbladder cancer	29.9	KRAS MLH1 MUC2
18	microinvasive gastric cancer	29.9	CDX2 MLH1 MUC2
19	colon adenocarcinoma	29.8	KRAS KRT20 MLH1
20	vulva adenocarcinoma	29.7	CDKN2A CDX2 KRT20 KRT7
21	cystadenoma	29.6	KRT20 KRT7 MUC1 MUC2
22	cystic teratoma	29.6	CDX2 KRT20 KRT7 MUC2 NKX2-1
23	adenoid cystic carcinoma	29.6	KRAS KRT20 KRT7 MUC1
24	endocervical adenocarcinoma	29.2	CDKN2A CDX2 KRT20 KRT7
25	adenocarcinoma in situ	29.1	CDKN2A CDX2 KRAS KRT20 KRT7
26	large cell neuroendocrine carcinoma	28.9	EGFR KRT20 KRT7 NKX2-1
27	peritoneal mesothelioma	28.9	CDKN2A EGFR MUC1
28	mucoepidermoid carcinoma	28.8	EGFR KRT7 MUC1 MUC2
29	gastrointestinal stromal tumor	28.7	CDKN2A EGFR KRAS
30	thymus cancer	28.6	EGFR KRT7 MUC1 NKX2-1
31	adenocarcinoma	28.6	ALK CDKN2A EGFR KRAS MLH1 MUC1
32	appendix cancer	28.6	CDX2 KRAS KRT20 KRT7 MUC1 MUC2
33	transitional cell carcinoma	28.3	CDKN2A EGFR KRT20 KRT7
34	small intestinal adenocarcinoma	28.2	CDX2 EGFR KRAS MUC1 MUC2
35	horseshoe kidney	28.0	CDX2 EGFR KRT20 KRT7 NKX2-1
36	renal cell carcinoma, nonpapillary	27.9	EGFR KRT20 KRT7 MUC1 NKX2-1
37	pancreas adenocarcinoma	27.9	CDKN2A EGFR KRAS MUC1 MUC2
38	endometrial cancer	27.8	CDKN2A EGFR KRAS KRT7 MLH1
39	gastric cancer	27.3	CDKN2A CDX2 EGFR KRAS MLH1 MUC2
40	colorectal adenocarcinoma	26.9	CDX2 EGFR KRAS KRT20 KRT7 MLH1
41	ovarian cancer	26.8	EGFR KRAS KRT7 MLH1 MUC1 MUC2
42	colorectal cancer	25.9	CDKN2A CDX2 EGFR KRAS KRT20 MLH1
43	lung cancer susceptibility 3	25.1	ALK CDKN2A CDX2 EGFR KRAS KRT20
44	colon mucinous adenocarcinoma	12.2
45	mucinous adenocarcinoma of ovary	12.2
46	mucinous adenocarcinoma of the appendix	12.1
47	cervical mucinous adenocarcinoma	12.0
48	ampulla of vater mucinous adenocarcinoma	12.0
49	bile duct mucinous adenocarcinoma	12.0
50	uterine ligament mucinous adenocarcinoma	12.0

Graphical network of the top 20 diseases related to Mucinous Adenocarcinoma:

Sources

Symptoms & Phenotypes for Mucinous Adenocarcinoma

GenomeRNAi Phenotypes related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-2	9.81	EGFR KRAS MUC1
2	Decreased viability	GR00106-A-0	9.81	KRAS
3	Decreased viability	GR00221-A-1	9.81	EGFR KRAS ALK CDKN2A
4	Decreased viability	GR00221-A-2	9.81	KRAS
5	Decreased viability	GR00221-A-3	9.81	CDKN2A
6	Decreased viability	GR00221-A-4	9.81	CDKN2A EGFR ALK
7	Decreased viability	GR00301-A	9.81	KRAS
8	Decreased viability	GR00381-A-1	9.81	KRAS
9	Decreased viability	GR00402-S-2	9.81	EGFR KRAS ALK CDKN2A MUC1
10	Decreased cell migration	GR00055-A-1	9.26	EGFR KRAS ALK MUC1

MGI Mouse Phenotypes related to Mucinous Adenocarcinoma:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.03	NKX2-1 EGFR KRAS KRT7 CDKN2A MLH1
2	endocrine/exocrine gland	MP:0005379	9.97	NKX2-1 ALK KRAS CDKN2A MLH1 CDX2
3	homeostasis/metabolism	MP:0005376	9.97	EGFR NKX2-1 ALK KRAS KRT7 CDKN2A
4	digestive/alimentary	MP:0005381	9.95	KRAS CDKN2A MLH1 CDX2 MUC2 EGFR
5	neoplasm	MP:0002006	9.86	KRAS ALK CDKN2A MLH1 CDX2 MUC2
6	reproductive system	MP:0005389	9.5	EGFR NKX2-1 ALK KRAS CDKN2A MLH1
7	pigmentation	MP:0001186	9.46	EGFR ALK KRAS CDKN2A
8	respiratory system	MP:0005388	9.1	EGFR NKX2-1 ALK KRAS CDKN2A MLH1

Sources

Drugs & Therapeutics for Mucinous Adenocarcinoma

Drugs for Mucinous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 213)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Bevacizumab

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

216974-75-3

Capecitabine

Approved, Investigational

Phase 3,Phase 2,Phase 1

154361-50-9

60953

Cetuximab

Approved

Phase 3,Phase 2,Phase 1,Early Phase 1

205923-56-4

56842117 2333

Fluorouracil

Approved

Phase 3,Phase 2,Phase 1

51-21-8

3385

Irinotecan

Approved, Investigational

Phase 3,Phase 2,Phase 1

97682-44-5, 100286-90-6

60838

Levoleucovorin

Approved, Investigational

Phase 3,Phase 2,Phase 1

68538-85-2

Oxaliplatin

Approved, Investigational

Phase 3,Phase 2,Phase 1

61825-94-3

5310940 9887054 43805 6857599

Carboplatin

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

41575-94-4

10339178 498142 38904

Paclitaxel

Approved, Vet_approved

Phase 3,Phase 2,Phase 1,Not Applicable

33069-62-4

36314

Doxorubicin

Approved, Investigational

Phase 3,Phase 2,Phase 1

23214-92-8

31703

Cisplatin

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

15663-27-1

84093 441203 2767

Lenograstim

Approved, Investigational

Phase 3,Phase 2,Phase 1

135968-09-1

Docetaxel

Approved, Investigational

Phase 3,Phase 2,Phase 1

114977-28-5

148124

Everolimus

Approved

Phase 2, Phase 3,Phase 1

159351-69-6

6442177

Miconazole

Approved, Investigational, Vet_approved

Phase 2, Phase 3,Phase 1

22916-47-8

4189

Sirolimus

Approved, Investigational

Phase 2, Phase 3,Phase 1

53123-88-9

5284616 6436030 46835353

Topotecan

Approved, Investigational

Phase 2, Phase 3,Phase 3,Phase 1

119413-54-6, 123948-87-8

60700

Cyclophosphamide

Approved, Investigational

Phase 3,Phase 2,Phase 1

50-18-0, 6055-19-2

2907

Gemcitabine

Approved

Phase 3,Phase 1,Phase 2

95058-81-4

60750

Metformin

Approved

Phase 2, Phase 3,Phase 1

657-24-9

14219 4091

Olaparib

Approved

Phase 2, Phase 3,Phase 1

763113-22-0

23725625

Letrozole

Approved, Investigational

Phase 2, Phase 3,Phase 3

112809-51-5

3902

Tamoxifen

Approved

Phase 2, Phase 3

10540-29-1

2733526

Trametinib

Approved

Phase 2, Phase 3,Phase 1

871700-17-3

11707110

Mitoxantrone

Approved, Investigational

Phase 3

65271-80-9

4212

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 3,Phase 2,Phase 1,Not Applicable

59-30-3

6037

leucovorin

Approved, Nutraceutical

Phase 3,Phase 2,Phase 1,Not Applicable

58-05-9

143 6006

Glutamic Acid

Approved, Nutraceutical

Phase 3,Phase 1

56-86-0

33032

Citric Acid

Approved, Nutraceutical, Vet_approved

Phase 2, Phase 3

77-92-9

311

Camptothecin

Experimental

Phase 3,Phase 2,Phase 1

7689-03-4

Doxil

Approved June 1999

Phase 3,Phase 2,Phase 1

31703

Cediranib

Investigational

Phase 2, Phase 3,Phase 1

288383-20-0

9933475

Maleic acid

Experimental

Phase 2, Phase 3,Phase 1

110-16-7

444266

Alkylating Agents

Phase 3,Phase 2,Phase 1

Angiogenesis Inhibitors

Phase 3,Phase 2,Phase 1

Angiogenesis Modulating Agents

Phase 3,Phase 2,Phase 1

Anti-Bacterial Agents

Phase 3,Phase 2,Phase 1

Antibiotics, Antitubercular

Phase 3,Phase 2,Phase 1

Antidotes

Phase 3,Phase 2,Phase 1

Antimetabolites

Phase 3,Phase 2,Phase 1

Antimetabolites, Antineoplastic

Phase 3,Phase 2,Phase 1

Antineoplastic Agents, Phytogenic

Phase 3,Phase 2,Phase 1,Not Applicable

Calcium, Dietary

Phase 3,Phase 2,Phase 1

Immunosuppressive Agents

Phase 3,Phase 2,Phase 1

Micronutrients

Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Mitomycins

Phase 3

Nucleic Acid Synthesis Inhibitors

Phase 3

Protective Agents

Phase 3,Phase 2,Phase 1

topoisomerase I inhibitors

Phase 3,Phase 2,Phase 1

Topoisomerase Inhibitors

Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 188)

#	Name	Status	NCT ID	Phase	Drugs
1	Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer	Unknown status	NCT01167725	Phase 3	FOLFIRI regimen;FOLFOX regimen;capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;mitomycin C;oxaliplatin
2	Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal Cancer	Unknown status	NCT00002896	Phase 3	chemotherapy;fluorouracil;leucovorin calcium
3	High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer	Completed	NCT00004150	Phase 3	fluorouracil;leucovorin calcium
4	Edrecolomab in Treating Patients With Stage II Colon Cancer	Completed	NCT00002968	Phase 3
5	Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer	Completed	NCT00005036	Phase 3	irinotecan hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
6	Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	Completed	NCT00262847	Phase 3	Carboplatin;Paclitaxel
7	Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer	Completed	NCT00002568	Phase 3	cisplatin;paclitaxel
8	Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer	Completed	NCT00483782	Phase 3	carboplatin;paclitaxel
9	Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer	Completed	NCT00002717	Phase 3	cisplatin;paclitaxel
10	Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer	Completed	NCT00003322	Phase 3	cisplatin;paclitaxel
11	Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer	Completed	NCT00003644	Phase 3	carboplatin;paclitaxel
12	Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer	Completed	NCT00006011	Phase 3	Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
13	Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Recruiting	NCT00719303	Phase 3
14	Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol	Recruiting	NCT02501954	Phase 3	Cisplatin;Carboplatin;Paclitaxel
15	Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer	Recruiting	NCT03422198	Phase 3
16	Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Recruiting	NCT02839707	Phase 2, Phase 3	Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
17	Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	Active, not recruiting	NCT00565851	Phase 3	Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
18	Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer	Active, not recruiting	NCT01167712	Phase 3	Carboplatin;Paclitaxel
19	Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer	Active, not recruiting	NCT00108745	Phase 3	Paclitaxel;Paclitaxel Poliglumex
20	Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer	Active, not recruiting	NCT00217737	Phase 3	Fluorouracil;Leucovorin Calcium;Oxaliplatin
21	Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Active, not recruiting	NCT00951496	Phase 3	Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
22	Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation	Active, not recruiting	NCT03285802	Phase 2, Phase 3	Letrozole;Everolimus
23	Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer	Active, not recruiting	NCT01081262	Phase 3	Capecitabine;Carboplatin;Oxaliplatin;Paclitaxel
24	Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer	Active, not recruiting	NCT02101788	Phase 2, Phase 3	Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen Citrate;Topotecan Hydrochloride;Trametinib
25	Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer	Active, not recruiting	NCT00942357	Phase 3	Carboplatin;Cisplatin;Paclitaxel
26	Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer	Active, not recruiting	NCT02065687	Phase 2, Phase 3	Carboplatin;Metformin Hydrochloride;Paclitaxel
27	Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer	Active, not recruiting	NCT00807768	Phase 3	Carboplatin;Paclitaxel
28	Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Suspended	NCT02502266	Phase 2, Phase 3	Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
29	Comparison of Adjuvant Chemotherapy Regimens in Treating Patients With Stage II or Stage III Rectal Cancer Who Are Receiving Radiation Therapy and Fluorouracil Before or After Surgery	Terminated	NCT00068692	Phase 3	capecitabine;fluorouracil;leucovorin calcium;irinotecan hydrochloride;oxaliplatin
30	Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer	Terminated	NCT00003880	Phase 2, Phase 3	carboplatin;paclitaxel
31	Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer	Terminated	NCT00002819	Phase 3	carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
32	Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy	Withdrawn	NCT01492920	Phase 3
33	Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer	Unknown status	NCT02112552	Phase 2	Paclitaxel;Carboplatin
34	VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Unknown status	NCT01666444	Phase 2	pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
35	Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer	Unknown status	NCT00017303	Phase 2	carboplatin;oglufanide disodium;paclitaxel
36	Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy	Completed	NCT00004547	Phase 2	Postoperative dwell with paclitaxel and 5-FU
37	Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer	Completed	NCT01196429	Phase 2	Carboplatin;Docetaxel;Paclitaxel;Temsirolimus
38	Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin	Completed	NCT00993616	Phase 2	belinostat;carboplatin
39	A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Completed	NCT00939809	Phase 2
40	Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy	Completed	NCT00466960	Phase 2	paclitaxel albumin-stabilized nanoparticle formulation
41	Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma	Completed	NCT00059787	Phase 2	paclitaxel;carboplatin;erlotinib
42	Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer	Completed	NCT01225887	Phase 2	Nintedanib
43	Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer	Completed	NCT01642082	Phase 2
44	Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer	Completed	NCT00888173	Phase 2	Brivanib Alaninate
45	Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer	Completed	NCT00100841	Phase 2	oxaliplatin;leucovorin calcium;fluorouracil
46	Papillary Serous Carcinoma of the Endometrium	Completed	NCT00515073	Phase 2	Paclitaxel;Dexamethasone;Cimetidine;Diphenhydramine
47	Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma	Completed	NCT00506779	Phase 1, Phase 2	Imatinib Mesylate;Paclitaxel
48	A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma	Completed	NCT00231868	Phase 2	Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
49	S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer	Completed	NCT00008138	Phase 2	carboplatin;paclitaxel
50	Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Completed	NCT00003944	Phase 2	carboplatin;cyclophosphamide;paclitaxel;topotecan hydrochloride

Search NIH Clinical Center for Mucinous Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma, mucinous

Sources

Genetic Tests for Mucinous Adenocarcinoma

Sources

Anatomical Context for Mucinous Adenocarcinoma

MalaCards organs/tissues related to Mucinous Adenocarcinoma:

⁴¹

Colon, Prostate, Appendix, Lung, Ovary, Liver, Pancreas

Sources

Publications for Mucinous Adenocarcinoma

Articles related to Mucinous Adenocarcinoma:

(show top 50) (show all 593)

#	Title	Authors	Year
1	Hemorrhagic Brain Metastases in a Patient with Anaplastic Lymphoma Kinase (ALK)-Rearranged Invasive Mucinous Adenocarcinoma of the Lung. ( 29371584 )	Shi M....Georgescu M.M.	2018
2	Mucinous Adenocarcinoma of the Scalp: Primary Cutaneous Neoplasm Versus Underlying Metastatic Disease. ( 29876191 )	Brown C.A....Ueno C.M.	2018
3	Right-colon mucinous adenocarcinoma mimicking a hydatid cyst. ( 29313694 )	IbA!A+ez N....Parrilla P.	2018
4	GATA6-positive lung adenocarcinomas are associated with invasive mucinous adenocarcinoma morphology, hepatocyte nuclear factor 4I+ expression, and KRAS mutations. ( 29469192 )	Nakajima N....Haga H.	2018
5	Multicystic mucinous adenocarcinoma of the uterine cervix compared with benign multicystic lesions: Multiparametric MR features. ( 29624774 )	Song J....Chen T.	2018
6	Case of mucinous adenocarcinoma of the lung associated with congenital pulmonary airway malformation in a neonate. ( 29441110 )	Koh J....Kim E.A.	2018
7	Primary Mucinous Adenocarcinoma of Skin: Myoepithelial Cells are a Clue to its Diagnosis. ( 29692460 )	Sistla R....Narayanswamy J.	2018
8	Duodenal mucinous adenocarcinoma presenting as ileus, obstructive jaundice and massive ascites: A case report. ( 29456851 )	Ding D....Zhang S.	2018
9	Mucinous adenocarcinoma arising from chronic perianal fistula mimicking horseshoe abscess. ( 29622704 )	Prasad S.N....Lal H.	2018
10	Laparoscopic abdominoperineal resection for the treatment of a mucinous adenocarcinoma associated with an anal fistula. ( 29593864 )	Chrysikos D....Theodoropoulos G.	2018
11	Acinar-Predominant Pattern Correlates With Poorer Prognosis in Invasive Mucinous Adenocarcinoma of the Lung. ( 29538611 )	Lin G....Xie C.	2018
12	Pseudomyxoma Peritonei Arising From Urachal Mucinous Adenocarcinoma. ( 29024737 )	Dimopoulos P....Liyanage S.	2018
13	Frequent <i>NRG1</i> fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression. ( 29515761 )	Trombetta D....Muscarella L.A.	2018
14	Perianal Mucinous Adenocarcinoma Diagnosed by Histological Study of Anorectal Abscess with Fistula. ( 29577055 )	Jee S.L....Jabar M.F.	2018
15	Perianal Paget disease secondary to pagetoid spread of mucinous adenocarcinoma of the anal canal. ( 29400297 )	Matos-Pires E....Mendes-Bastos P.	2018
16	Diagnosis, clinicopathological characteristics and prognosis of pulmonary mucinous adenocarcinoma. ( 29375717 )	Sun F....Lu K.	2018
17	Rare Case of Iliopsoas Abscess Secondary to Mucinous Adenocarcinoma of the Colon: A Case Report. ( 29854689 )	Menon A....Jakkan M.S.	2018
18	FOXM1 activates AGR2 and causes progression of lung adenomas into invasive mucinous adenocarcinomas. ( 29267283 )	Milewski D....Kalin T.V.	2017
19	Mucinous adenocarcinoma and non-mucinous adenocarcinoma: differing clinicopathological characteristics and computed tomography features in gastric cancer. ( 28501848 )	Zhao J....Zhang W.	2017
20	Characteristics and prognostic factors of colorectal mucinous adenocarcinoma with signet ring cells. ( 29138597 )	Kong X....Li J.	2017
21	Mucinous adenocarcinoma with lepidic pattern and with K-RAS mutation in a newborn with antenatal diagnosis of congenital pulmonary airway malformation. ( 28889407 )	Stephanov O....Sartelet H.	2017
22	Mucinous adenocarcinoma arising in an end ileostomy - a video vignette. ( 28677338 )	JimAcnez RodrA-guez R.M....de la Portilla F.	2017
23	Primary Mucinous Adenocarcinoma of the Thymus: A Case Report and Literature Review. ( 28956749 )	Yin Y.G....Lu H.Z.	2017
24	Comment on: External Validation of the Simplified Preoperative Assessment for Low-Grade Mucinous Adenocarcinoma of the Appendix. ( 29124485 )	Dineen S.P....Fournier K.F.	2017
25	Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases. ( 28590015 )	Samaratunga H....Egevad L.	2017
26	Primary mucinous adenocarcinoma of the vulva, intestinal type. ( 28791269 )	Lee I.H....Lee K.H.	2017
27	Fluorodeoxyglucose-avid pulmonary mucinous adenocarcinoma presenting with nonfluorodeoxyglucose-avid cystic brain lesions of unknown etiopathology: Brain magnetic resonance imaging and fluorodeoxyglucose-positron emission tomography-computed tomography imaging features and additional value of whole-body positron emission tomography acquisition. ( 29199669 )	Shinde V....Basu S.	2017
28	Cystic metastasis from a mucinous adenocarcinoma of duodenum mimicking type II choledochal cyst: A case report. ( 29290919 )	Kim Y.N....Song J.S.	2017
29	The Importance of Appendectomy in Surgery for Mucinous Adenocarcinoma of the Ovary. ( 28060142 )	Rosendahl M....gdall C.K.	2017
30	Mixed mucinous adenocarcinoma and somatostatinoma of the ampulla of Vater associated with neurofibromatosis type 1. ( 28693748 )	Reynolds R....Marjoniemi V.	2017
31	Mucinous adenocarcinoma of unknown primary presenting with dysphagia. ( 29223385 )	Nagpal S.J.S....Topazian M.D.	2017
32	Mucinous adenocarcinoma in association with hidradenitis suppurativa. ( 28597923 )	Alkeraye S....Mortier L.	2017
33	Pulmonary Invasive Mucinous Adenocarcinoma and Mixed Invasive Mucinous/Non-Mucinous Adenocarcinoma- A Clinicopathological and Molecular Genetic Study with Survival Analysis. ( 28823574 )	Boland J.M....Yi E.S.	2017
34	Giant mucinous adenocarcinoma of the appendix: a case report. ( 28756772 )	Dang S.C....Chen J.X.	2017
35	Molecular characteristics of multifocal invasive mucinous adenocarcinoma of the lung: Report of a rare case. ( 28851076 )	Tian Y....Guo Z.	2017
36	Mucinous adenocarcinoma in association with hidradenitis suppurativa: a new example of isoscartopic response. ( 29271499 )	De Vita V....Ruocco E.	2017
37	Sonographic image of cervix epithelioid trophoblastic tumor coexisting with mucinous adenocarcinoma in a postmenopausal woman: A case report. ( 28930821 )	Zhu Y....He R.	2017
38	Sertoli-Leydig cell tumor of the ovary masquerading as a mucinous adenocarcinoma: a frozen section pitfall. ( 29081925 )	Zuckerman J.E....Moatamed N.A.	2017
39	Agenesis of the dorsal pancreas associated with mucinous adenocarcinoma and cystic teratoma: a case report and literature review. ( 28174646 )	Saikaly E....El Rassi Z.	2017
40	Synchronous mucinous adenocarcinoma of the recto sigmoid revealed by and seeding an anal fistula. (A case report and review of the literature). ( 28641190 )	Spiridakis K.G....Christodoulakis M.S.	2017
41	Biology of invasive mucinous adenocarcinoma of the lung. ( 29114467 )	Cha Y.J....Shim H.S.	2017
42	Invasive mucinous adenocarcinoma with lepidic-predominant pattern coexisted with tuberculosis: a case report. ( 28687977 )	Xu X....Kang J.	2017
43	Size of Non-lepidic Invasive Pattern Predicts Recurrence in Pulmonary Mucinous Adenocarcinoma: Morphologic Analysis of 188 Resected Cases with Reappraisal of Invasion Criteria. ( 27744658 )	Hwang S....Choi Y.S.	2017
44	Mucinous adenocarcinoma on perianal fistula. A rising entity? ( 28929316 )	Alvarez-Laso C.J....RodrA-guez R.	2017
45	Urachal mucinous adenocarcinoma with pseudomyxoma peritonei: A case report. ( 28858081 )	Liang L....Guo J.	2017
46	Vulvar Carcinosarcoma Composed of Intestinal-type Mucinous Adenocarcinoma Associated With Anaplastic Pleomorphic and Spindle Cell Carcinoma and Heterologous Chondrosarcomatous and Osteosarcomatous Elements: A Case Report and Review of the Literature. ( 28319579 )	Lordello L....Oliva E.	2017
47	Presentation of mucinous adenocarcinoma of renal pelvis masquerading as gross hydronephrosis: A histopathological surprise. ( 28702413 )	Patel K.N....Gandhi S.P.	2017
48	KRAS mutation-positive mucinous adenocarcinoma originating in the thymus. ( 28932588 )	Sakanoue I....Takahashi Y.	2017
49	Prognosis of Signet Ring Cell Carcinoma of the Colon and Rectum and their Distinction of Mucinous Adenocarcinoma with Signet Ring Cells. A Comparative Study. ( 28785968 )	Pozos-Ochoa L.I....Salcedo-HernA!ndez R.A.	2017
50	Metastatic Mucinous Adenocarcinoma and Carcinoid Tumor Arising From a Mature Cystic Teratoma of a Horseshoe Kidney. ( 28083486 )	Higgins A....Williams H.	2017

Sources

Genes for Mucinous Adenocarcinoma

Genes related to Mucinous Adenocarcinoma (0 elite genes):

(show all 12)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	KRT7	Keratin 7	Protein Coding	24.16	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
2	MUC2	Mucin 2, Oligomeric Mucus/Gel-Forming	Protein Coding	23.93	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	23.9	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	CDX2	Caudal Type Homeobox 2	Protein Coding	23.75	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	ALK	ALK Receptor Tyrosine Kinase	Protein Coding	22.44	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	KRT20	Keratin 20	Protein Coding	22.37	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	NKX2-1	NK2 Homeobox 1	Protein Coding	22.34	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	MUC1	Mucin 1, Cell Surface Associated	Protein Coding	22.27	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	MLH1	MutL Homolog 1	Protein Coding	22.26	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	EGFR	Epidermal Growth Factor Receptor	Protein Coding	22.02	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	21.85	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	NRG1	Neuregulin 1	Protein Coding	21.7	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Mucinous Adenocarcinoma

Sources

Expression for Mucinous Adenocarcinoma

Search GEO for disease gene expression data for Mucinous Adenocarcinoma.

Sources

Pathways for Mucinous Adenocarcinoma

Pathways related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 13)

#	Super pathways	Score	Top Affiliating Genes
1	Pathways in cancer ³⁷	12.38	ALK CDKN2A EGFR KRAS MLH1
2	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ¹	12.15	EGFR KRAS MUC1 NRG1
3	Glioma ³⁷ Show member pathways EGFR tyrosine kinase inhibitor resistance ³⁷ Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Signaling Pathways in Glioblastoma ¹	12.02	ALK CDKN2A EGFR KRAS NRG1
4	Colorectal Cancer Metastasis ⁶⁴	11.89	EGFR KRAS MLH1
5	Tyrosine Kinases / Adaptors ⁴	11.82	ALK EGFR NRG1
6	Gastric cancer ³⁷ Show member pathways Breast cancer ³⁷ Hepatocellular carcinoma ³⁷	11.77	CDKN2A CDX2 EGFR KRAS MLH1 MUC2
7	Signaling by PTK6 ⁶⁶ Show member pathways PTK6 Activates STAT3 ⁶⁶ PTK6 Down-Regulation ⁶⁶ PTK6 Expression ⁶⁶ PTK6 promotes HIF1A stabilization ⁶⁶ PTK6 Regulates Proteins Involved in RNA Processing ⁶⁶ PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases ⁶⁶ PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 ⁶⁶ RAS signaling downstream of NF1 loss-of-function variants ⁶⁶	11.75	EGFR KRAS NRG1
8	Glioblastoma Multiforme ⁶⁴	11.65	CDKN2A EGFR KRAS
9	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ¹ Nuclear signaling by ERBB4 ⁶⁶	11.61	EGFR KRAS NRG1
10	Bladder cancer ³⁷ ¹	11.36	CDKN2A EGFR KRAS
11	Agrin Interactions at Neuromuscular Junction ⁶⁴	11.08	EGFR KRAS NRG1
12	G-protein signaling_K-RAS regulation pathway ²²	10.96	EGFR KRAS
13	EGFR Transactivation by Gastrin ⁶⁶ Show member pathways EGFR-dependent Endothelin signaling events ¹ SHC-related events triggered by IGF1R ⁶⁶	10.93	EGFR KRAS

Sources

GO Terms for Mucinous Adenocarcinoma

Biological processes related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of gene expression	GO:0010628	9.67	CDKN2A KRAS NKX2-1 NRG1
2	peptidyl-tyrosine phosphorylation	GO:0018108	9.61	ALK EGFR NRG1
3	stimulatory C-type lectin receptor signaling pathway	GO:0002223	9.43	KRAS MUC1 MUC2
4	positive regulation of cellular senescence	GO:2000774	9.4	CDKN2A KRAS
5	epithelial tube branching involved in lung morphogenesis	GO:0060441	9.32	KRAS NKX2-1
6	negative regulation of ERBB signaling pathway	GO:1901185	9.16	EGFR NRG1
7	cerebral cortex cell migration	GO:0021795	8.96	EGFR NKX2-1
8	ERBB2 signaling pathway	GO:0038128	8.8	EGFR KRAS NRG1

Molecular functions related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein tyrosine kinase activity	GO:0004713	8.8	ALK EGFR NRG1

Sources

Sources for Mucinous Adenocarcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia